bioSeedin’s Post

View organization page for bioSeedin, graphic

5,549 followers

𝐒𝐢𝐥𝐞𝐧𝐜𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐬 𝐏𝐨𝐬𝐢𝐭𝐢𝐯𝐞 𝐏𝐡𝐚𝐬𝐞 𝟐 𝐃𝐚𝐭𝐚 𝐟𝐨𝐫 𝐙𝐞𝐫𝐥𝐚𝐬𝐢𝐫𝐚𝐧 𝐢𝐧 𝐂𝐚𝐫𝐝𝐢𝐨𝐯𝐚𝐬𝐜𝐮𝐥𝐚𝐫 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐒𝐭𝐮𝐝𝐲 Silence Therapeutics plc, Nasdaq: SLN (“Silence”) Silence Therapeutics plc, a pioneering biotechnology company dedicated to combatting diseases with precision engineered medicines, announces positive 36-week data from the ongoing ALPACAR-360 phase 2 study of zerlasiran (SLN360) in 178 subjects with baseline lipoprotein(a), or Lp(a), levels at or over 125 nmol/L, at high risk of atherosclerotic cardiovascular disease (ASCVD) events. Zerlasiran, a siRNA, aims to lower Lp(a), a significant genetic risk factor for cardiovascular disease affecting up to 20% of the global population. In the double-blind placebo-controlled period, zerlasiran was administered at 300 mg subcutaneously every 16 or 24 weeks and 450 mg every 24 weeks to patients with a median baseline Lp(a) of approximately 215 nmol/L. Significant reduction from baseline in Lp(a) compared to placebo was observed at 36 weeks (primary endpoint). Median percentage reduction in Lp(a) of 90% or greater were noted for both doses at week 36. No new safety concerns emerged during this period. The 60-week study continues, with secondary endpoints including change in Lp(a) from baseline to 48 weeks, 60 weeks, and potential effects on other lipids/lipoproteins to be evaluated. “We are encouraged by the phase 2 data, consistent with phase 1 results, supporting zerlasiran as a competitive treatment for patients with high Lp(a),” said Steven Romano, MD Steve Romano, Head of Research and Development at Silence. “We anticipate reporting topline 48-week data in the second quarter of this year.” #Zerlasiran #CardiovascularDisease #Phase2Study #Biotechnology #PrecisionMedicine #HealthcareInnovation #Lipoprotein #HeartHealth #Research #MedicalAdvancements

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics